A trial of pexastimogene devacirepvec [Pexa-Vec] in combination with immune checkpoint inhibitors in cancer patients
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Pexastimogene devacirepvec (Primary) ; Durvalumab; Tremelimumab
- Indications Colorectal cancer
- Focus Adverse reactions
- 10 Oct 2017 Planned initiation date changed from 11 Oct 2017 to 18 Oct 2017.
- 05 Oct 2017 Planned initiation date changed from 11 Jul 2017 to 11 Oct 2017.
- 05 Oct 2017 Status changed from not yet recruiting to recruiting.